Lipschütz acute vulvar ulcer related to COVID-19 vaccination: First case report in South America.

Lipschütz ulcer is a non-sexually transmitted genital lesion of unknown etiology, which presents as a painful vulvar ulcer. Lipschütz ulcers have been described in most continents. This is the first case reported in Peru and South America. We present the case of a 33-year-old female patient with a Lipschütz ulcer after being vaccinated with the second dose of the AstraZeneca COVID-19 vaccine. She reported having had only one sexual partner in her lifetime. Laboratory results were negative for herpes simplex 2, Cytomegalovirus, Toxoplasma gondii, Epstein-Barr virus, and syphilis. The patient received symptomatic treatment. Ten days after the onset, the patient was significantly better during follow-up. This case report displays a potential adverse effect of the AstraZeneca COVID-19 vaccine as a Lipschütz ulcer triggered by the host humoral immune response. However, further research is needed to establish the causal relationship between these two.

La úlcera de Lipschütz es una lesión genital no transmitidas por vía sexual de etiología desconocida, se presenta como una úlcera vulvar muy dolorosa. Las úlceras de Lipschütz se han descrito en la mayoría de los continentes. Este es el primer caso que se reporta en Perú y Sudamérica. En este reporte de caso se presentauna paciente de 33 años con una úlcera de Lipschütz luego de haber sido vacunada con la segunda dosis de la vacuna AstraZeneca COVID-19. Refirió haber tenido una sola pareja sexual a lo largo de su vida. Los resultados de laboratorio fueron negativos para herpes simplex 2, Citomegalovirus, Toxoplasma gondii, virus de Epstein-Barr y sífilis. La paciente recibió tratamiento sintomático. Diez días después, durante el seguimiento, la paciente estaba significativamente mejor. Este reporte de caso expone un potencial efecto adverso de la vacuna AstraZeneca COVID-19, en forma de úlcera de Lipschütz, desencadenado por la respuesta inmune humoral del huésped. Sin embargo, es necesario realizar más investigación para establecer la relación causal entre ambos.

Lipschütz acute vulvar ulcer related to COVID-19 vaccination: First case report in South America / Úlcera vulvar aguda de Lipschütz relacionada con la vacunación por COVID-19: primer caso notificado en Sudamérica

Lipschütz ulcer is a non-sexually transmitted genital lesion of unknown etiology, which presents as a painful vulvar ulcer. Lipschütz ulcers have been described in most continents. This is the first case reported in Peru and South America. We present the case of a 33-year-old female patient with a Lipschütz ulcer after being vaccinated with the second dose of the AstraZeneca COVID-19 vaccine. She reported having had only one sexual partner in her lifetime. Laboratory results were negative for herpes simplex 2, Cytomegalovirus, Toxoplasma gondii, Epstein-Barr virus, and syphilis. The patient received symptomatic treatment. Ten days after the onset, the patient was significantly better during follow-up. This case report displays a potential adverse effect of the AstraZeneca COVID-19 vaccine as a Lipschütz ulcer triggered by the host humoral immune response. However, further research is needed to establish the causal relationship between these two.

La úlcera de Lipschütz es una lesión genital no transmitidas por vía sexual de etiología desconocida, se presenta como una úlcera vulvar muy dolorosa. Las úlceras de Lipschütz se han descrito en la mayoría de los continentes. Este es el primer caso que se reporta en Perú y Sudamérica. En este reporte de caso se presentauna paciente de 33 años con una úlcera de Lipschütz luego de haber sido vacunada con la segunda dosis de la vacuna AstraZeneca COVID-19. Refirió haber tenido una sola pareja sexual a lo largo de su vida. Los resultados de laboratorio fueron negativos para herpes simplex 2, Citomegalovirus, Toxoplasma gondii, virus de Epstein-Barr y sífilis. La paciente recibió tratamiento sintomático. Diez días después, durante el seguimiento, la paciente estaba significativamente mejor. Este reporte de caso expone un potencial efecto adverso de la vacuna AstraZeneca COVID-19, en forma de úlcera de Lipschütz, desencadenado por la respuesta inmune humoral del huésped. Sin embargo, es necesario realizar más investigación para establecer la relación causal entre ambos.

Level of Knowledge Regarding Mpox among Peruvian Physicians during the 2022 Outbreak: A Cross-Sectional Study.

Introduction: Due to the high incidence of mpox in Peru and the poor knowledge about this disease among healthcare workers in non-endemic countries, it is crucial to determine the knowledge status of Peruvian physicians. Methodology: We conducted an analytical cross-sectional study based on an online survey from August to September 2022. Physicians who had a medical license and lived and practiced medicine in Peru were included. To evaluate the factors associated with a higher level of knowledge, we used crude (cPR) and adjusted (aPR) prevalence ratios with 95% confidence intervals (95% CI) using Poisson regression. Results: We included 463 physicians. The mean age was 36.6 (SD: 10.3) years, and most were male (58.1%). Regarding knowledge, the median knowledge score was 14 [IQR: 13 to 15] out of 17 points. In terms of knowledge gaps, only 60.7% of the participants knew that there was an FDA-approved vaccine for mpox, 49.0% of participants knew about mpox proctitis and 33.3% acknowledged that it could be transmitted by the bite of an infected rodent. We found that taking care of patients with mpox (aPR: 1.39; 95% CI: 1.13 to 1.72) was associated with higher knowledge (>p50), while living in the eastern macro-region (aPR: 0.62; 95% CI: 0.42 to 0.93) was associated with lower knowledge (≤p50). Conclusions: Our study showed a high level of knowledge about mpox among Peruvian physicians. However, educational campaigns may be necessary, especially for physicians from the eastern region and those who do not have clinical experience with mpox.

Inequalities in infant vaccination coverage during the COVID-19 pandemic: A population-based study in Peru.

OBJECTIVE: To identify the associated factors and assess the inequalities of full vaccination coverage (FVC) among Peruvian infants aged 12-23 months during the COVID-19 pandemic in a nationally representative sample. METHODS: We carried out a population-based cross-sectional study based on a secondary data analysis using the 2021 Peruvian Demographic Health Survey (DHS) in infants aged 12 to 23 months. The sampling design was probabilistic, multistage, stratified, and independent at both departmental and area of residence levels. FVC was defined according to the WHO definition. We performed generalized linear models (GLM) Poisson family log link function to estimate crude (aPR) and adjusted prevalence ratios (aPR). Also, for inequality assessment, we calculated the concentration curve (CC), concentration index (CI), and Erreygers normalized concentration index (ECI). RESULTS: We included 4,189 infants in our analysis. Nationwide, the prevalence of FVC was 66.19% (95% CI: 64.33-68). Being younger, having a mother with no education or primary education, belonging to a large family, having no access to mass media, having had six or fewer ANC visits, and having a mother whose age was under 20 at first delivery were inversely associated with FVC. Meanwhile, living in the Highlands or on the rest of the coast, and living in rural areas were directly associated with FVC. We found a pro-rich inequality in FVC based on wealth-ranked households (CI: 0.0066; ECI: 0.0175). CONCLUSION: FVC has dropped among Peruvian infants aged between 12 and 23 months. There were several factors associated with FVC. It was more concentrated among the better-off infants, although in low magnitude.

Factors Associated With Drug Consumption Without Scientific Evidence in Patients With Mild COVID-19 in Peru.

OBJECTIVE: This study aimed to evaluate the factors associated with the consumption of drugs without scientific evidence in patients with mild COVID-19 infection in Peru. METHODS: An analytical cross-sectional study was carried out including 372 adult patients with a history of mild COVID-19 disease. Factors associated with drug consumption were evaluated by Poisson regressions with robust variance adjustment using the bootstrapping resampling method. RESULTS: Seventy-two percent consumed some medication without scientific evidence, with antibiotics (71%) and ivermectin for human use (68%) being the most commonly used. Factors associated with the consumption of drugs to treat mild COVID-19 infection were thinking that the drugs are not effective (adjusted prevalence ratio, 0.55; 95% confidence interval, 0.41-0.74) and not being informed about the efficacy of the drugs (adjusted prevalence ratio, 0.48; 95% confidence interval, 0.36-0.65). CONCLUSIONS: Education of the population seems to be the main factor that increases the consumption of drugs without scientific evidence in the Peruvian population to treat mild COVID-19.

Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.

OBJECTIVE: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. METHODS: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. RESULTS: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15-1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09-1.28) or jungle (RPa: 1.30; 95% CI: 1.15-1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06-1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17-1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29-1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). CONCLUSION: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.

Association of lifetime e-cigarette and/or tobacco use and last year cannabis use among university students: A cross-sectional secondary analysis of a national survey.

BACKGROUND: The accelerated increase in the use of e-cigarette by university students in recent years has incremented nicotine use in addition to tobacco, but it is not known whether the use of cannabis is related to these alternatives. This study analyzes the association between the use of electronic cigarettes and/or tobacco and the use of cannabis in the last 12 months. An analytical cross-sectional study conducted based on the III Andean epidemiological study on drug consumption among university students in 2016. A multivariate analysis performed using a generalized linear family model and the log Poisson link option. The results were shown as Prevalence Ratios (PR) in raw (PRc) and adjusted (PRa) models, and the analysis also employed 95% confidence intervals (95% CI) for the percentages. SETTING: Ten Peruvian universities. PARTICIPANTS: University students' lifetime. EXPOSURE: Participants' e-cigarette and/or tobacco consumption, based on questions about consumption of tobacco and e-cigarettes. Participants were categorized into those consuming: only e-cigarettes, only tobacco, both, or neither. OUTCOME: The use of cannabis by participants in the last 12 months. Among the university students who met the inclusion criteria (n = 3981), the prevalence of using both e-cigarettes and tobacco (dual) throughout life was 11.6% (95% CI: 10.1 to 13.3), and only e-cigarettes was 1.2% (95% CI: 0.7 to 1.8). The use of cannabis in the last 12 months was 5.2% (95% CI: 4.1 to 6.5). Results of this study found a sequential probability gradient of cannabis use, where those with dual use had 58.5 times more probability of having used cannabis in the last 12 months (PRa 58.5, 95% CI: 20.9 to 163.7, p <0.001) compared to those who used none; whereas those who used only tobacco were 33.3 times more likely to have used cannabis in the last 12 months (PRa 33.3, 95% CI: 11.9 to 93.2, p <0.001), those who reported using only e-cigarette had 9.8 times more probability of having used cannabis in the last 12 months (PRa 9.8, 95% CI: 1.6 to 60.4, p = 0.014). We found an increase in the probability of having used cannabis in the last 12 months among university students who reported tobacco and/or e-cigarettes use. A sequential probability gradient was found and it showed that, in comparison to students who informed being nonusers of tobacco and/or e-cigarette, university students who were lifetime dual users were most likely to having used cannabis in the last 12 months, followed by those reporting an exclusive lifetime use of tobacco, as well as those students who reported an exclusive lifetime use of e-cigarettes. It is necessary to raise awareness of the association of tobacco and e-cigarette use with an increased possibility of using cannabis. Studies are needed in different cultural contexts to investigate the progression of electronic cigarette and/or tobacco use, as well as their dosage, intensity of use, concurrent use, and neurological and behavioral mechanisms that are related to the use of cannabis and other illegal drugs that may increase dependence and mental health problems.

Prácticas de prevención y control frente a la infección por Sars-Cov2 en la población peruana / Prevention and control practices against Sars-Cov2 infection in the peruvian population

Objetivo: Describir las prácticas de prevención y control para la infección por SARS-CoV2 en la población peruana. Material y Métodos: Estudio observacional de tipo descriptivo. Se evaluó una muestra no probabilística de adultos residentes en algún departamento de Perú. Las prácticas preventivas fueron evaluadas en personas sin antecedente de COVID-19 y las prácticas de control en personas que lo habían padecido. Resultados: Se evaluó un total de 3630 peruanos (edad media 25,4 ± 9,5) de los cuales el 3231 no indicaban el antecedente de COVID-19 y 399 refirieron haberlo padecido. Las medidas de prevención y control que se realizaron a menudo o siempre con mayor frecuencia fueron el utilizar mascarilla al salir de casa (97,9% vs 87,7), cubrirse su nariz y boca al estornudar o toser (95,4% vs 89,9%), guardar distancia de los demás en la calle (91,4% vs 74,7%), realizar el lavado de manos con agua y jabón al volver a casa (92,5% vs 88,7%), y desinfectar las superficies de objetos y lugares personales (82,6% vs 77,4%). El 22,1% y 83,7%, el 59,7% y 80,2, y el 8,0% y 16,8% consumieron algún tipo de medicamento, planta medicinal y dióxido de cloro para la prevención y control de la infección de COVID-19, respectivamente. Conclusiones: En general, menos del 50% de los participantes realizaron prácticas de prevención y control frente a la COVID-19 a menudo o siempre.

Objective: To describe prevention and control practices for SARS-CoV2 infection in the Peruvian population. Material and Methods: Observational descriptive study. A non-probabilistic sample of adults residing in a Peruvian department was evaluated. Preventive practices were evaluated in people with no history of COVID-19 and control practices in people who had had COVID-19. Results: A total of 3630 Peruvians were evaluated (mean age 25.4 ± 9.5) of whom 3231 did not indicate a history of COVID-19 and 399 reported having suffered from it. The prevention and control measures most frequently or always performed were using a mask when leaving home (97.9% vs 87.7%), covering their nose and mouth when sneezing or coughing (95.4% vs 89.9%), keeping their distance from others in the street (91.4% vs 74.7%), washing hands with soap and water when returning home (92.5% vs 88.7%), and disinfecting surfaces of objects and personal places (82.6% vs 77.4%). 22.1% and 83.7%, 59.7% and 80.2, and 8.0% and 16.8% consumed some type of medication, medicinal plant, and chlorine dioxide for prevention and control of COVID-19 infection, respectively. Conclusions: Overall, less than 50% of the participants performed prevention and control practices against COVID-19 often or always.